Clinical Trials on Metabolic X Syndrome Dyslipidemia

Total 8439 results

GlaxoSmithKline

Completed

GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

Dyslipidaemia | Dyslipidaemias

Germany, Estonia, Belgium, France, Netherlands, Denmark, Portugal, Norway, Sweden, Lithuania, Finland
Merck Sharp & Dohme LLC

Terminated

MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)

Metabolic X Syndrome Dyslipidemia
GlaxoSmithKline

Completed

Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.

Healthy Subjects | Dyslipidaemia | Dyslipidaemias

United Kingdom
University of Pennsylvania
Abbott

Completed

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

Metabolic Syndrome x

United States
Fundación para el Fomento de la Investigación Sanitaria...
AINIATechnology Center

Completed

Effects of a Bakery Product Enriched With Fibre and L-carnitine on Insulin Resistance in Patients With Metabolic Syndrome

Overweight | Dyslipidemias | Metabolic X Syndrome
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia

Dyslipidaemia

Denmark, United States, Slovakia
Novartis Pharmaceuticals

Completed

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Dyslipidaemia

Jordan, United States, Taiwan
AstraZeneca

Completed

48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

Dyslipidaemia
Patrice D. Cani
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Evaluation of the Effects Associated With the Administration of Akkermansia Muciniphila on Parameters of Metabolic Syndrome (Microbes4U)

Glucose Metabolism Disorders | Obesity | Dyslipidemias | Metabolic Syndrome x

Belgium
Xention Ltd

Completed

Study of the Electrocardiographic Effects of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Statin Therapy Results in the Real World Practice in the Czech Republic (STEP)

Dyslipidaemia

Czech Republic
Foundation Research, Florida
GlaxoSmithKline; Abbott; Kos Pharmaceuticals

Completed

Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia

Insulin Resistance | Metabolic Syndrome X

United States
Laval University
Canadian Institutes of Health Research (CIHR)

Completed

Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome (MCT)

Metabolic Syndrome X

Canada
GlaxoSmithKline

Completed

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

Dyslipidaemias

United States
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome

Dyslipidemias | Metabolic Syndrome X

United States
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Dyslipidaemias

United States, Canada
GlaxoSmithKline

Completed

Study to Test GSK256073 in Patients With Dyslipidemia

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

Dyslipidaemias

United States
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP) (STARSHIP)

Hypercholesterolemia | Dyslipidaemia
AstraZeneca

Completed

CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) (CEPHEUSII)

Dyslipidaemia

Russian Federation
Xention Ltd

Completed

Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES) (ARIES)

Hypercholesterolemia | Dyslipidaemia
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
AstraZeneca

Completed

Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

Dyslipidaemia

Russian Federation
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS) (IRIS)

Hypercholesterolemia | Dyslipidaemia
GWT-TUD GmbH
Technische Universität Dresden; University of Regensburg

Completed

Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome

Metabolic Syndrome | Dyslipidaemia

Germany
GlaxoSmithKline

Completed

Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers

Healthy Subjects | Dyslipidaemias

United States
GlaxoSmithKline

Completed

A Second Study to Determine the Effect of GSK256073A on HVTs

Healthy Subjects | Dyslipidaemias

United States
Wageningen University
Unilever R&D; Netherlands Heart Foundation

Completed

MARIS Study; Mediterranean Approach to Reduce Insulin-Resistance Study

Hypertension | Overweight | Insulin Resistance | Dyslipidemia | Metabolic Syndrome X

Netherlands
AstraZeneca

Completed

IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin

Fredrickson Type IIa & Type IIb Dyslipidaemia
NeuroBo Pharmaceuticals Inc.

Completed

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

Severe Hypertriglyceridemia | Mixed Dyslipidaemia

United States, Canada
Aga Khan University

Completed

Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia

Hypertension | Diabetes Mellitus | Hypercholesterolemia | Metabolic Syndrome X

Pakistan
Rush University Medical Center

Completed

Reducing Disparities in Late Life Depression and Metabolic Syndrome (BRIGHTEN-Heart)

Hyperglycemia | Hypertension | Obesity | Overweight | Dyslipidemias | Depressive Symptoms | Metabolic Syndrome X

United States
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR)

Completed

Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol

Insulin Resistance | Dyslipidaemia

Canada
Gary Van Guilder
Western Colorado University; Auckland University of Technology

Completed

The Dose-response Effects of High Intensity Functional Training on Metabolic Syndrome Risk Factors

Metabolic Syndrome | Insulin Resistance | Endothelial Dysfunction | Atherogenic Dyslipidemia

United States
GlaxoSmithKline

Completed

A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers

Healthy Subjects | Dyslipidaemias

United States
Washington University School of Medicine
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) (ARCH-MS)

Hypertension | Overweight | Dyslipidemias | Prediabetic State | Metabolic Syndrome X

United States
Washington University School of Medicine
National Heart, Lung, and Blood Institute (NHLBI); Singulex

Completed

Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS) (ARCH-MS)

Hypertension | Overweight | Dyslipidemias | Prediabetic State | Metabolic Syndrome X

United States
GlaxoSmithKline

Completed

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

Obesity | Hypercholesterolemia | Dyslipidaemias

United States
GlaxoSmithKline

Terminated

Effect Of GW501516X On How The Heart Obtains And Uses Energy

Heart Failure | Dyslipidaemias

United States
Arrowhead Pharmaceuticals

Active, not recruiting

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (ARCHES-2)

Mixed Dyslipidemia

United States, Australia, Canada, New Zealand
Yooyoung Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin

Combined Dyslipidemia

Korea, Republic of
Société des Produits Nestlé (SPN)

Completed

Effect of a Low Fat Milk Product on Lipids Profile in Dyslipidemia Subjects (Lipidown)

Primary Dyslipidemia

China
Provident Clinical Research
Reliant Pharmaceuticals

Unknown

An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin

Mixed Dyslipidemia
AstraZeneca

Completed

A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome

Metabolic Syndrome | Dyslipidemia

Australia
Hanlim Pharm. Co., Ltd.

Recruiting

An Observational Study on the Identification of Prescription Patterns of STAFEN Cap

Mixed Dyslipidemia

Korea, Republic of
IlDong Pharmaceutical Co Ltd

Not yet recruiting

A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe

Mixed Dyslipidemia
Arrowhead Pharmaceuticals

Completed

Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR)

Mixed Dyslipidemia

United States, Australia, Poland, New Zealand, Canada, Hungary
Provident Clinical Research
Reliant Pharmaceuticals

Completed

An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia

Mixed Dyslipidemia

Clinical Trials on Metabolic X Syndrome Dyslipidemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations